The Moscow Seed Fund and nanotech centre Technospark have invested $156k in company NSL’s medical laser drill. The instrument is designed for contactless puncturing of the finger tissue for blood analysis. The money will allow NSL to take the drill into mass production.
$86k of the investment came from the Moscow Seed Fund, with Technospark providing the other $70k. This is the 30th project to receive funding from the Moscow Seed Fund, and the first in the medical sector.
The laser drill is an alternative to the blood lancet or traditional needle. Its use avoids any risk of infection for both the patient and medical personnel, and minimalises feelings of nausea or faintness when taking blood. According to the company, using its laser drill rather than imported blood lancets would save more than $13 million per year.
NSL was founded in February 2014 with the participation of the Engineering Centre of New Technologies and Technospark. The idea of forming a joint company in order to launch the laser drill into mass production was judged to be in the favour of both parties. The prototype of the ErbiLite laser drill has been built and is currently undergoing testing in order to be licensed by the Department of Healt